Anaptysbio, Inc
ANAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001370053
No open-market purchases or sales by Anaptysbio, Inc insiders were filed in the last 90 days; 213 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Anaptysbio, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Anaptysbio, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Orwin John A | Director | 17,995 | Sep 17, 2026 | 4 |
| Lizzul Paul F. | Chief Medical Officer | 42,088 | Aug 7, 2026 | 5 |
| Faga Daniel | President, CEO | 495,965 | Aug 7, 2026 | 6 |
| Renton Hollings | Director | 10,995 | Jun 17, 2026 | 3 |
| Schmid John P. | Director | 37,652 | Jun 17, 2026 | 5 |
| Hughes Owen | Director | – | May 13, 2026 | 1 |
| Murphy Christopher M. | Chief Financial Officer | – | May 13, 2026 | 1 |
| Gray Susannah | Director | – | Apr 29, 2026 | 1 |
| Loumeau Eric J | CHIEF LEGAL OFFICER | 12,835 | Feb 13, 2026 | 7 |
| Marquet Magda | Director | 9,930 | Jan 16, 2026 | 2 |
| Mulroy Dennis | CHIEF FINANCIAL OFFICER | 21,852 | Jan 9, 2026 | 5 |
| Fenton Dennis M | Director | 4,965 | Jan 8, 2026 | 1 |
| Jain Rita | Director | 11,864 | Jan 8, 2026 | 1 |
| Ware J. Anthony | Director | 9,630 | Jan 8, 2026 | 2 |
| Nodelman Oleg | Director, 10% Owner | 7,880,094Indirect | Jan 2, 2025 | 0 |
| EcoR1 Capital, LLC | Director, 10% Owner | 7,880,094Indirect | Jan 2, 2025 | 0 |
| Topper James N | Director, 10% Owner | – | Jan 10, 2023 | 0 |
| Hamill Laura | Director | – | Jan 10, 2023 | 0 |
| Suria Hamza | President, CEO | 68,600 | Feb 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 (view filing) | Jan 7 | 1 day | Mulroy DennisCHIEF FINANCIAL OFFICER | SSale | −1.91K | $45.11 | −$86.1K | −9.7%17.7K after | |
| Jan 8, 2026 (view filing) | Jan 7 | 1 day | Faga DanielPresident, CEO | SSale | −9.20K | $45.11 | −$415.1K | −1.9%466.8K after | |
| Jan 8, 2026 (view filing) | Jan 7 | 1 day | Lizzul Paul F.Chief Medical Officer | SSale | −2.23K | $45.11 | −$100.8K | −5.7%37.2K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Loumeau Eric JCHIEF LEGAL OFFICER | SSale | −2.21K | $44.71 | −$98.8K | −14.7%12.8K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Mulroy DennisCHIEF FINANCIAL OFFICER | SSale | −2.52K | $44.71 | −$112.4K | −10.3%21.9K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Faga DanielPresident, CEO | SSale | −14.3K | $44.71 | −$638.5K | −2.9%479.3K after | |
| Jan 9, 2026 (view filing) | Jan 8 | 1 day | Lizzul Paul F.Chief Medical Officer | SSale | −3.65K | $44.71 | −$163.2K | −8.0%42.1K after | |
| Jan 16, 2026 (view filing) | Jan 15 | 1 day | Marquet MagdaDirector | SSale | −11.0K | $48.23 | −$530.6K | −52.6%9.93K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Loumeau Eric JCHIEF LEGAL OFFICER | SSale | −10.0K | $54.00 | −$540.0K | −43.8%12.8K after | 10b5-1 |
| Mar 27, 2026 (view filing) | Mar 27 | Same day | Faga DanielPresident, CEO | SSale | −17.7K | $61.61 | −$1.09M | −3.4%496.0K after | 10 lots |
| Apr 1, 2026 (view filing) | Mar 30 | 2 days | Schmid John P.Director | SSale | −20.6K | $56.11 | −$1.16M | −39.5%31.6K after | 3 lots |